TOPIC: One Lot of Tyenne Injection 400 mg/20 ml Vials by Fresenius Kabi: Recall - Due to Presence of Glass Particles
AUDIENCE: Patient, Health Care Professional, Pharmacy, Pulmonary, Hematology, Pediatric, Cardiology
ISSUE: Fresenius Kabi is recalling one lot of Tyenne Injection 400 mg/20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles.
Risk Statement: The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More seriously, glass particles can cause blockage and clotting in blood vessels, which can cut off blood flow to vital organs, lead to a life-threatening blood clot in the lungs (pulmonary embolism) and cause permanent organ damage or death.
Product was distributed nationwide to wholesalers, distributors and direct customers.
For more information about this recall, click on the red button "Read Recall" below.
BACKGROUND: Tyenne Injection is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs); adult patients with giant cell arteritis; patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis; patients 2 years of age and older with active systemic juvenile idiopathic arthritis; adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome; and certain hospitalized adult patients with COVID-19.
RECOMMENDATIONS:
-
Patients should contact their physician or health care provider if they have experienced any problems that may be related to receiving this drug product.
-
Consumers with questions regarding this recall can contact Fresenius Kabi USA Quality Assurance at 1-866-716-2459, send an e-mail to either productcomplaint.USA@fresenius-kabi.com or adverse.events.USA@fresenius-kabi.com.
-
If health care facilities have any of the affected lot, they are to immediately discontinue distributing, dispensing, or using the lot and return all units to Fresenius Kabi.
|
